Evaluate Vantage Homepage
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.